Mucor

Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, August 9, 2023
BioNTech, CT, Nephrotoxicity, IV, Diabetes, Hospital, Mucor, Conference call, Clinical trial, Women's Hospital International and Fertility Centre, Infection, Brain, LNC, Research, Biomedical Research, European Congress of Ethnic Religions, Messenger, Lung, Acute myeloid leukemia, Development, MRI, Kidney, National Resilience Institute, ECCMID, MD, Patient, Standard of care, Azole, Microsoft Access, RNA interference, Fungal infection, FDA, Nationwide, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, Conference, NYSE, Food, Female, Pharmaceutical industry, Medical imaging, Antifungal

BEDMINSTER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) --  Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three and six months ended June 30, 2023 and provides a business update.

Key Points: 
  • Matinas’ collaboration with National Resilience continues to focus on in vitro and in vivo delivery of mRNA and expects initial data later in 2023.
  • The Company reported no revenue for the second quarter of 2023 compared with $1.1 million of revenue for the second quarter of 2022, which was generated from the Company’s research collaborations with BioNTech SE.
  • Total costs and expenses for the second quarter of 2023 were $6.2 million compared with $7.0 million for the second quarter of 2022.
  • The net loss for the second quarter of 2023 was $6.1 million, or $0.03 per share, compared with a net loss for the second quarter of 2022 of $5.9 million, or $0.03 per share.

Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use

Retrieved on: 
Monday, June 12, 2023
Research, Technology, Infectious Diseases, Other Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, EUA, UDM, Hair, Infection, Bachelor, BMB, Allergy, Workflow, RPP, Culture, SARS-CoV-2, Software, Pneumocystis jirovecii, COVID-19, Eye, Aspergillus, Histoplasma capsulatum, CE marking, PCR, Nomenclature codes, Immunochemistry, Emergency Use Authorization, Federal Food, Drug, and Cosmetic Act, Panel, Coccidioides, RSV, RUO, Patient, Laboratory, Autoimmune disease, Molecular Probes, IVD, Growth, GPP, Immunodeficiency, Diagnosis, FDA, Mucor, Virus, Vaccine, Rhizopus, Applied Spectral Imaging, Rhizomucor, Fusarium, Cunninghamella, Cryptococcus

The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.

Key Points: 
  • The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.
  • Applied BioCode’s Fungal Panel is intended for research use only and may be used in infectious disease research or pharmaceutical development.
  • “Applied BioCode is thrilled to announce our first release of an RUO panel under our new product strategy.
  • Applied BioCode, Inc. has also been granted an Emergency Use Authorization (EUA) from the U.S. FDA for its BioCode® SARS-CoV-2 Flu Plus Assay ⱡ, BioCode® SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*.

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Retrieved on: 
Monday, January 30, 2023
Transfer, Biomedical Advanced Research and Development Authority, RNA, Necessity and sufficiency, Disease, Lipofectamine, Food, Phase II, Safety, Oligonucleotide, Mycosis, Attention, HeLa, Mucormycosis, NYSE, BioNTech, Gene expression, Evaluation, Mucor, Sirna, Vaccine, ASO, Cryptococcosis, Aspergillosis, Survival, Therapy, Conference, Gilead, BARDA, Internal, COVID, HEK293, Patient, Enactment, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Aspergillus, LNC, Organic acid, Hand, Candidiasis, Genentech, Coccidioidomycosis, Medicine, Asos, Development, RNA transfection, Sirna Therapeutics, Toxicity, Fine chemical, Pharmaceutical industry, Matina Brothers

ET

Key Points: 
  • ET
    BEDMINSTER, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB, Matinas), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today is providing a business update on its ongoing programs and discussing its strategic outlook for 2023.
  • Our ongoing collaborations with BioNTech and, recently, National Resilience, have aligned Matinas with two of the world’s leading companies in the gene therapy space.
  • The Company will host a live conference call and webcast to discuss this corporate update and 2023 business outlook today, Monday, January 30 at 4:30 p.m.
  • The live webcast will be accessible on the Investors section of Matinas BioPharma’s website, www.matinasbiopharma.com , and archived for 90 days.

AgroFresh and Ceradis Sign Exclusive Distribution Agreement for CeraFruta®, an Organic Biofungicide

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Food chain, Partnership, EPA, Food industry, Ingredient, Mucor, Canker, Citrus, NASDAQ, Solution, Agtech, Food loss and waste, OMRI, Wageningen University & Research, Natamycin, Management control system, Marketing, Agriculture, Renewable energy

Were excited to collaborate with the team at Ceradis on this innovative new organic solution, helping our customers continue to find the most sustainable ways to deliver fresh produce to global consumers.

Key Points: 
  • Were excited to collaborate with the team at Ceradis on this innovative new organic solution, helping our customers continue to find the most sustainable ways to deliver fresh produce to global consumers.
  • CeraFruta also controls mucor and sour rots, post-harvest diseases that currently cannot be adequately controlled by industry-standard synthetic fungicides.
  • As an organic best-in-class solution for post-harvest decay, CeraFruta fulfills an important role in the food chain.
  • Under the new agreement, AgroFresh will be the exclusive market channel for CeraFruta in the post-harvest market in the US.